C50.119: Malignant neoplasm of central portion of unspecified female breast

C50.119, malignant neoplasm of central portion of unspecified female breast, is listed as a covered diagnosis in 7 Medicare billing and coding articles that apply to 65 HCPCS Level II codes, including L8035 (Custom breast prosthesis, post mastectomy, molded to…), L8002 (Breast prosthesis, mastectomy bra, with integrated breast…), L8001 (Breast prosthesis, mastectomy bra, with integrated breast…). 6 of these codes have a 2026 DMEPOS fee schedule amount; L8035 pays $4,403.11 to $5,283.69 depending on the state. The articles come from 3 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.

HCPCS Level II codes with C50.119 as a covered diagnosis

CodeDescriptionMedicare coverageDMEPOS fee 2026 (state range)Articles listing it
L8035Custom breast prosthesis, post mastectomy, molded to patient model, any typeSpecial coverage instructions apply$4,403.11–$5,283.691
L8002Breast prosthesis, mastectomy bra, with integrated breast prosthesis form, bilateral, any size, any typeSpecial coverage instructions apply$198.27–$218.121
L8001Breast prosthesis, mastectomy bra, with integrated breast prosthesis form, unilateral, any size, any typeSpecial coverage instructions apply$150.77–$165.831
L8015External breast prosthesis garment, with mastectomy form, post mastectomySpecial coverage instructions apply$72.05–$86.411
L8000Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any typeSpecial coverage instructions apply$44.70–$78.161
A4280Adhesive skin support attachment for use with external breast prosthesis, eachCarrier judgment$7.38–$8.131
J9217Leuprolide acetate (for depot suspension), 7.5 mgSpecial coverage instructions apply—1
J1952Leuprolide injectable, camcevi, 1 mgCarrier judgment—1
J3315Injection, triptorelin pamoate, 3.75 mgSpecial coverage instructions apply—1
J1954Injection, leuprolide acetate for depot suspension (lutrate depot), 7.5 mgCarrier judgment—1
J9202Goserelin acetate implant, per 3.6 mgSpecial coverage instructions apply—1
J1950Injection, leuprolide acetate (for depot suspension), per 3.75 mgSpecial coverage instructions apply—1
J9219Leuprolide acetate implant, 65 mgSpecial coverage instructions apply—1
J9225Histrelin implant (vantas), 50 mgSpecial coverage instructions apply—1
Q0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day periodSpecial coverage instructions apply—2
Q0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day periodSpecial coverage instructions apply—2
Q5129Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mgCarrier judgment—1
Q5126Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mgCarrier judgment—1
Q5118Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mgCarrier judgment—1
Q5107Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mgSpecial coverage instructions apply—1
J9035Injection, bevacizumab, 10 mgCarrier judgment—1
J3590Unclassified biologicsCarrier judgment—1
C9257Injection, bevacizumab, 0.25 mgSpecial coverage instructions apply—1
Q5160Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mgCarrier judgment—1
J9267Injection, paclitaxel, 1 mgSpecial coverage instructions apply—1

40 more codes are listed. See every code with payment by region in Caduvo.

Medicare policy articles listing C50.119

A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.

Other C50 diagnoses (Malignant neoplasm of breast)

Frequently asked questions

Does Medicare cover C50.119 (Malignant neoplasm of central portion of unspecified…)?

Medicare covers items and services, not diagnoses. 7 Medicare billing and coding articles list C50.119 as a covered diagnosis for 65 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.

Which HCPCS codes can be billed with ICD-10 C50.119?

The Level II codes from the policies most specific to this diagnosis are L8035 (Custom breast prosthesis, post mastectomy, molded to…, 1 article); L8002 (Breast prosthesis, mastectomy bra, with integrated breast…, 1 article); L8001 (Breast prosthesis, mastectomy bra, with integrated breast…, 1 article); L8015 (External breast prosthesis garment, with mastectomy form…, 1 article); L8000 (Breast prosthesis, mastectomy bra, without integrated…, 1 article). Code choice depends on the item supplied; check each code's descriptor.

What does Medicare pay for equipment billed with C50.119?

Under the 2026 DMEPOS fee schedule (non-rural state fees): L8035 $4,403.11 to $5,283.69; L8002 $198.27 to $218.12; L8001 $150.77 to $165.83; L8015 $72.05 to $86.41. Medicare pays 80% of the allowed amount after the Part B deductible.

Which Medicare policy articles list C50.119?

A52478 (External Breast Prostheses - Policy Article); A59160 (Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs); A52370 (Billing and Coding: Bevacizumab and biosimilars), and 4 more articles.

What is ICD-10-CM code C50.119?

C50.119 is the ICD-10-CM code for malignant neoplasm of central portion of unspecified female breast, in category C50 (Malignant neoplasm of breast), chapter 2: Neoplasms.

Next steps

Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.

Chapter 2: Neoplasms · All diagnoses · HCPCS lookup